Cork-based medical diagnostics start-up Radisens Diagnostics has been contracted by the National Health Service (NHS) East of England to integrate a kidney test into its chronic care assay panel for long-term disease management.
Radisens Diagnostics has the only point-of-care platform to integrate immunoassay, biochemistry and haematology tests onto a single mini-disc panel, to diagnose and monitor patients for multiple chronic and acute care conditions.
This project targets the integration of a creatinine (kidney) test onto Radisens’ lon-term chronic care panel. Using a finger prick of blood applied to the panel, the Radisens diagnostic device returns results within minutes.
This chronic care panel will enable the GP to actively monitor long-term chronic disease patients for diabetes, heart disease, hypertension and chronic kidney disease, resulting in better patient care and significant productivity gains and efficiencies in the healthcare system.
Jerry O’Brien, Radisens Diagnostics’ CEO, said: " Decentralising the long-term disease management to point of care leads to significantly improved patient care, and productivity gains and efficiencies within the healthcare system".
Small business research initiative
The Radisens Diagnostics contract is part of the East of England Small Business Research Initiative, which looks to industry to commercialise innovation that can be shown to make a difference to the care of people with long-term conditions.
“It is estimated that around one in three people are living with a long-term condition which not only creates real personal challenges, but also increases the cost of healthcare. New technologies will mean that in the future, more people will be able to receive treatment in their own homes, with their condition monitored and managed without having to visit or stay in a hospital,” said Karen Livingstone, director of strategic partnerships at NHS East of England.
“This not only makes for an improved patient experience but also saves healthcare resources and costs which currently amount to £7 out of every £10 being spent on long-term conditions.”